{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:49:16Z","timestamp":1749649756440},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to evaluate the effect of baseline low-density lipoprotein cholesterol (LDL-C) on the outcomes of patients with the acute coronary syndrome (ACS) receiving pitavastatin monotherapy or the combination of pitavastatin\u2009+\u2009ezetimibe. In the HIJ-PROPER study, 1734 ACS patients with dyslipidemia were randomly assigned to receive pitavastatin or pitavastatin\u2009+\u2009ezetimibe therapy. Statin-na\u00efve participants (n\u2009=\u20091429) were divided into two groups based on the median LDL-C level (131\u00a0mg\/dL) at enrollment. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, and ischemia-driven coronary revascularization. The median follow-up was 3.2\u00a0years. In the\u2009&lt;\u2009131\u00a0mg\/dL group (n\u2009=\u2009686), LDL-C changes were \u2212\u200934.0% and \u2212\u200949.8% in the pitavastatin monotherapy and pitavastatin\u2009+\u2009ezetimibe-treated groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), respectively; in the\u2009\u2265\u2009131\u00a0mg\/dL group (n\u2009=\u2009743), LDL-C changes were \u2212\u200942.9% and \u2212\u200956.4% (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001, respectively. Kaplan\u2013Meier analyses revealed that the primary endpoint was not significantly different between the treatment groups for the\u2009&lt;\u2009131\u00a0mg\/dL group, however, it was significantly lower in patients treated with pitavastatin\u2009+\u2009ezetimibe in the\u2009\u2265\u2009131\u00a0mg\/dL group (Hazard ratio\u2009=\u20090.72, 95% confidence interval\u2009=\u20090.56\u20130.91, <jats:italic>P<\/jats:italic>\u2009=\u20090.007, <jats:italic>P<\/jats:italic> value for interaction\u2009=\u20090.012).\u00a0Statin-na\u00efve ACS patients with baseline LDL-C\u2009&lt;\u2009131\u00a0mg\/dL did not clinically benefit from pitavastatin\u2009+\u2009ezetimibe, while patients with baseline LDL-C\u2009\u2265\u2009131\u00a0mg\/dL treated with pitavastatin\u2009+\u2009ezetimibe showed better clinical results than those treated with pitavastatin monotherapy.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration<\/jats:bold>: Original HIJ PROPER study; URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.ac.jp\/ctr\">http:\/\/www.umin.ac.jp\/ctr<\/jats:ext-link>. Unique Identifier; UMIN000002742, registered as an International Standard Randomized Controlled Trial.<\/jats:p>","DOI":"10.1038\/s41598-021-87098-x","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T10:02:57Z","timestamp":1617616977000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-na\u00efve acute coronary syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Jihaeng","family":"Im","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erisa","family":"Kawada-Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Arashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"87098_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","volume":"93","author":"DD Waters","year":"2004","unstructured":"Waters, D. D. et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am. J. Cardiol. 93, 154\u2013158. https:\/\/doi.org\/10.1016\/j.amjcard.2003.09.031 (2004).","journal-title":"Am. J. Cardiol."},{"key":"87098_CR2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen, T. R. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA J. Am. Med. Assoc. 294, 2437\u20132445. https:\/\/doi.org\/10.1001\/jama.294.19.2437 (2005).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"87098_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495\u20131504. https:\/\/doi.org\/10.1056\/NEJMoa040583 (2004).","journal-title":"N. Engl. J. Med."},{"key":"87098_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"JA de Lemos","year":"2004","unstructured":"de Lemos, J. A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA J. Am. Med. Assoc. 292, 1307\u20131316. https:\/\/doi.org\/10.1001\/jama.292.11.1307 (2004).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"87098_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397. https:\/\/doi.org\/10.1056\/NEJMoa1410489 (2015).","journal-title":"N. Engl. J. Med."},{"key":"87098_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174 (2018).","journal-title":"N. Engl. J. Med."},{"key":"87098_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664 (2017).","journal-title":"N. Engl. J. Med."},{"key":"87098_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5 (2010).","journal-title":"Lancet"},{"key":"87098_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jacc.2008.05.046","volume":"52","author":"RR Giraldez","year":"2008","unstructured":"Giraldez, R. R. et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J. Am. Coll. Cardiol. 52, 914\u2013920. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.046 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"87098_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese, E. P. et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA J. Am. Med. Assoc. 319, 1566\u20131579. https:\/\/doi.org\/10.1001\/jama.2018.2525 (2018).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"87098_CR11","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","volume":"38","author":"N Hagiwara","year":"2017","unstructured":"Hagiwara, N. et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur. Heart J. 38, 2264\u20132276. https:\/\/doi.org\/10.1093\/eurheartj\/ehx162 (2017).","journal-title":"Eur. Heart J."},{"key":"87098_CR12","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"E Expert Panel on Detection","year":"2001","unstructured":"Expert Panel on Detection, E. & Treatment of High Blood Cholesterol in, A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA J. Am. Med. Assoc. 285, 2486\u20132497. https:\/\/doi.org\/10.1001\/jama.285.19.2486 (2001).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"87098_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","volume":"140","author":"PG Steg","year":"2019","unstructured":"Steg, P. G. et al. Effect of alirocumab on mortality after acute coronary syndromes. Circulation 140, 103\u2013112. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038840 (2019).","journal-title":"Circulation"},{"key":"87098_CR14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","volume":"75","author":"DL Bhatt","year":"2020","unstructured":"Bhatt, D. L. et al. Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial. J. Am. Coll. Cardiol. 75, 2297\u20132308. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.029 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"87098_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227\u2013239. https:\/\/doi.org\/10.1161\/01.CIR.0000133317.49796.0E (2004).","journal-title":"Circulation"},{"key":"87098_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267\u2013315. https:\/\/doi.org\/10.1093\/eurheartj\/ehv320 (2016).","journal-title":"Eur. Heart J."},{"key":"87098_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455 (2020).","journal-title":"Eur. Heart J."},{"key":"87098_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1053\/meta.2002.36298","volume":"51","author":"T Sudhop","year":"2002","unstructured":"Sudhop, T., Gottwald, B. M. & von Bergmann, K. Serum plant sterols as a potential risk factor for coronary heart disease. Metab. Clin. Exp. 51, 1519\u20131521. https:\/\/doi.org\/10.1053\/meta.2002.36298 (2002).","journal-title":"Metab. Clin. Exp."},{"key":"87098_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/s0002-9149(02)02774-1","volume":"90","author":"C Gagne","year":"2002","unstructured":"Gagne, C. et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90, 1084\u20131091. https:\/\/doi.org\/10.1016\/s0002-9149(02)02774-1 (2002).","journal-title":"Am. J. Cardiol."},{"key":"87098_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0021-9150(03)00106-0","volume":"168","author":"TA Miettinen","year":"2003","unstructured":"Miettinen, T. A. & Gylling, H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis 168, 343\u2013349. https:\/\/doi.org\/10.1016\/s0021-9150(03)00106-0 (2003).","journal-title":"Atherosclerosis"},{"key":"87098_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2018.04.036","volume":"274","author":"J Yamaguchi","year":"2018","unstructured":"Yamaguchi, J. et al. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: a sub-analysis of HIJ-PROPER. Atherosclerosis 274, 139\u2013145. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.04.036 (2018).","journal-title":"Atherosclerosis"},{"key":"87098_CR22","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. Circulation 139, e1082\u2013e1143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625 (2019).","journal-title":"Circulation"},{"key":"87098_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.amjmed.2015.10.024","volume":"129","author":"S Bangalore","year":"2016","unstructured":"Bangalore, S. et al. 2013 Cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis?. Am. J. Med. 129, 384\u2013391. https:\/\/doi.org\/10.1016\/j.amjmed.2015.10.024 (2016).","journal-title":"Am. J. Med."},{"key":"87098_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.amjcard.2013.10.038","volume":"113","author":"M Habara","year":"2014","unstructured":"Habara, M. et al. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am. J. Cardiol. 113, 580\u2013587. https:\/\/doi.org\/10.1016\/j.amjcard.2013.10.038 (2014).","journal-title":"Am. J. Cardiol."},{"key":"87098_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita, K. et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J. Am. Coll. Cardiol. 66, 495\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065 (2015).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87098-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:15:57Z","timestamp":1670048157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87098-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["87098"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-87098-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All members of the HIJ-PROPER study group received research support to perform clinical trials from the Japan Research Promotion Society for Cardiovascular Diseases, which is sponsored by Abbott Vascular Japan Co., Ltd., AstraZeneca K.K., Bayer Yakuhin Ltd., Boston Scientific Corporation, Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. NH reports honoraria from Bristol-Myers K.K. and Nippon Boehringer Ingelheim Co., Ltd., and grants from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd. JY and HO belong to the Clinical Research Division for Cardiovascular Catheter Intervention, which is financially maintained by donation from Abbott Vascular, Boston Scientific, Medtronic, and Terumo. The HIJ-PROPER Steering Committee has full access to all data of the present study and final responsibility for the decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"7480"}}